

Burden of HIV Comorbidities

Andrew Carr Centre for Applied Medical Research, and HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney, Australia

Burden of HIV Comorbidities End-organ toxicities













Burden of HIV Comorbidities Impact of specific SNAEs: AHOD

Coding of Death Classification ²	Number
Cancer	28
AIDS (ongoing active disease)	6
MI or other ischemic heart disease	5
Other heart or vascular disease	4
Suicide	3
Chronic viral hepatitis (progression of / complication to)	3
Renal failure	1
Other Causes	9
Unknown (autopsy inconclusive, died overseas, etc)	19
Missing information ³	19

AHOD report 2017











Burden of HIV Comorbidities Incidence following initial ART (START)

Endpoint	Events	n/100 pt-yrs	Death
Death	12	0.17	12*
Serious AIDS	14	0.20	1
tuberculosis	6	0.09	0
lymphoma	3	0.04	0
Kaposi's sarcoma	1	0.01	0
Serious non-AIDS	28	0.42	4

START study group, N Engl J Med 2015

Burden of HIV Comorbidities Incidence following initial ART (START)

Endpoint	Events	n/100 pt-yrs	Death
Death	12	0.17	12*
Serious AIDS	14	0.20	1
tuberculosis	6	0.09	0
lymphoma	3	0.04	0
Kaposi's sarcoma	1	0.01	0
Serious non-AIDS	28	0.42	4
CVD	12	0.17	3
cancer	9	0.13	1
renal failure	1		0
liver failure	0	0	0
Fracture	66	0.92	0

START study group, N Engl J Med 2015





Burden of HIV Comorbidities Complexity of care				
	What	Interval		
Organ				
CVD	ACC-AHA (including diabetes)	1-2 years		
Renal	eGFR / U _{Prot:Cr} / other causes	6 months		
Bone	DXA / FRAX / other causes	2-5 years		
CNS	Cogstate?; LP / MRI if symptomatic	12 months		
Cancer	Breast / bowel / lung / liver	As in HIV-		
	Pap smear	1-2 years		
Drug				
d4T / AZT	Lipoatrophy / fat accumulation	6 months		
PI	GI symptoms	every visit		
EFV	CNS symptoms	every visit		
RAL	Muscle pain / weakness	every visit		
DTG	CNS symptoms	every visit		

Burden of HIV Comorbidities Why comorbidities matter

- Affect multiple organs
- More common, in part due to ART
- Increase risk of death
- More common cause of morbidity and mortality than AIDS in patients on ART
- Increase complexity of care
 - more assessments
 - HIV disclosure / stigma
 - reduce ART adherence
 - reduce ART options
 - increase in polypharmacy
- Research should focus mainly on cardiovascular disease and cancers

Burden of HIV Comorbidities Disclosures

- Research funding/support: BMS, Gilead, Novartis and ViiV
- Conference travel sponsorships: BMS, Gilead and ViiV
- Advisory boards: Gilead, MSD and ViiV